236 related articles for article (PubMed ID: 36571701)
1. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R; Danese S; Zhou W; Klaff J; Ilo D; Yao X; Levy G; Higgins PDR; Loftus EV; Chen S; Gonzalez YS; Leonard C; Hébuterne X; Lindsay JO; Cao Q; Nakase H; Colombel JF; Vermeire S
Aliment Pharmacol Ther; 2024 Feb; 59(3):393-408. PubMed ID: 38010661
[TBL] [Abstract][Full Text] [Related]
4. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
5. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
Napolitano M; D'Amico F; Ragaini E; Peyrin-Biroulet L; Danese S
Drug Des Devel Ther; 2022; 16():1897-1913. PubMed ID: 35747444
[TBL] [Abstract][Full Text] [Related]
9. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
Law CCY; Kayal M; Mehandru S; Colombel JF
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
[TBL] [Abstract][Full Text] [Related]
10. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis.
Ismail M; Doelger E; Eckert D; Irvine AD; Chu AD; Teixeira HD; Liu W; Nader A
Br J Clin Pharmacol; 2023 Oct; 89(10):3139-3151. PubMed ID: 37232215
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
14. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
Loftus EV; Panés J; Lacerda AP; Peyrin-Biroulet L; D'Haens G; Panaccione R; Reinisch W; Louis E; Chen M; Nakase H; Begun J; Boland BS; Phillips C; Mohamed MF; Liu J; Geng Z; Feng T; Dubcenco E; Colombel JF
N Engl J Med; 2023 May; 388(21):1966-1980. PubMed ID: 37224198
[TBL] [Abstract][Full Text] [Related]
15. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
Raine T; Ishiguro Y; Rubin DT; Finney-Hayward T; Vladea R; Liu J; Phillips C; Cheng E; Targownik L; Loftus EV
J Crohns Colitis; 2024 May; 18(5):695-707. PubMed ID: 37942921
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
Danese S; Tran J; D'Haens G; Rubin DT; Aoyama N; Zhou W; Ilo D; Yao X; Sanchez Gonzalez Y; Panaccione R
Inflamm Bowel Dis; 2023 Nov; 29(11):1723-1729. PubMed ID: 36790041
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
19. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
20. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E; Thyssen JP; Silverberg JI; Papp KA; Paller AS; Weidinger S; Chih-Ho Hong H; Hendrickson B; Dilley D; Tenorio AR; Ladizinski B; Chu AD; Liu J; Irvine AD
J Allergy Clin Immunol; 2023 Jan; 151(1):172-181. PubMed ID: 36195170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]